Bone marrow-derived CMPs and GMPs represent highly functional proangiogenic cells

Implications for ischemic cardiovascular disease

Akm Khyrul Wara, Kevin Croce, Shi Yin Foo, Xinghui Sun, Basak Icli, Yevgenia Tesmenitsky, Fehim Esen, Anthony Rosenzweig, Mark W. Feinberg

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Clinical studies using bone marrow-derived proangiogenic cells (PACs) have demonstrated modest improvements of function and/or perfusion of ischemic myocardium or skeletal muscle. Because the identities of these PACs and their functional ability to promote neovascularization remain poorly understood, it is possible that a subset of robust PACs exists but is obscured by the heterogeneous nature of this cell population. Herein, we found that common myeloid progenitors (CMPs) and granulocyte-macrophage progenitors (GMPs) preferentially differentiate into PACs compared with megakaryocyte-erythrocyte progenitors, hematopoietic stem cells, and common lymphoid progenitors. In vivo hindlimb ischemia studies and Matrigel plug assays verified the enhanced neovascularization properties uniquely associated with PACs derived from CMPs and GMPs. Taken together, these observations identify CMPs and GMPs as key bone marrow progenitors for optimal PAC function in vitro and in vivo and provide a foundation for novel therapeutic approaches to modulate angiogenesis.

Original languageEnglish (US)
Pages (from-to)6461-6464
Number of pages4
JournalBlood
Volume118
Issue number24
DOIs
StatePublished - Dec 8 2011

Fingerprint

Myeloid Progenitor Cells
Granulocyte-Macrophage Progenitor Cells
Macrophages
Bone
Cardiovascular Diseases
Bone Marrow
Stem cells
Muscle
Assays
Megakaryocyte-Erythroid Progenitor Cells
Cells
Lymphoid Progenitor Cells
Hindlimb
Hematopoietic Stem Cells
Myocardium
Skeletal Muscle
Ischemia
Perfusion

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Bone marrow-derived CMPs and GMPs represent highly functional proangiogenic cells : Implications for ischemic cardiovascular disease. / Wara, Akm Khyrul; Croce, Kevin; Foo, Shi Yin; Sun, Xinghui; Icli, Basak; Tesmenitsky, Yevgenia; Esen, Fehim; Rosenzweig, Anthony; Feinberg, Mark W.

In: Blood, Vol. 118, No. 24, 08.12.2011, p. 6461-6464.

Research output: Contribution to journalArticle

Wara, AK, Croce, K, Foo, SY, Sun, X, Icli, B, Tesmenitsky, Y, Esen, F, Rosenzweig, A & Feinberg, MW 2011, 'Bone marrow-derived CMPs and GMPs represent highly functional proangiogenic cells: Implications for ischemic cardiovascular disease', Blood, vol. 118, no. 24, pp. 6461-6464. https://doi.org/10.1182/blood-2011-06-363457
Wara, Akm Khyrul ; Croce, Kevin ; Foo, Shi Yin ; Sun, Xinghui ; Icli, Basak ; Tesmenitsky, Yevgenia ; Esen, Fehim ; Rosenzweig, Anthony ; Feinberg, Mark W. / Bone marrow-derived CMPs and GMPs represent highly functional proangiogenic cells : Implications for ischemic cardiovascular disease. In: Blood. 2011 ; Vol. 118, No. 24. pp. 6461-6464.
@article{d2eaea82a52f464687232020e8ab41a9,
title = "Bone marrow-derived CMPs and GMPs represent highly functional proangiogenic cells: Implications for ischemic cardiovascular disease",
abstract = "Clinical studies using bone marrow-derived proangiogenic cells (PACs) have demonstrated modest improvements of function and/or perfusion of ischemic myocardium or skeletal muscle. Because the identities of these PACs and their functional ability to promote neovascularization remain poorly understood, it is possible that a subset of robust PACs exists but is obscured by the heterogeneous nature of this cell population. Herein, we found that common myeloid progenitors (CMPs) and granulocyte-macrophage progenitors (GMPs) preferentially differentiate into PACs compared with megakaryocyte-erythrocyte progenitors, hematopoietic stem cells, and common lymphoid progenitors. In vivo hindlimb ischemia studies and Matrigel plug assays verified the enhanced neovascularization properties uniquely associated with PACs derived from CMPs and GMPs. Taken together, these observations identify CMPs and GMPs as key bone marrow progenitors for optimal PAC function in vitro and in vivo and provide a foundation for novel therapeutic approaches to modulate angiogenesis.",
author = "Wara, {Akm Khyrul} and Kevin Croce and Foo, {Shi Yin} and Xinghui Sun and Basak Icli and Yevgenia Tesmenitsky and Fehim Esen and Anthony Rosenzweig and Feinberg, {Mark W.}",
year = "2011",
month = "12",
day = "8",
doi = "10.1182/blood-2011-06-363457",
language = "English (US)",
volume = "118",
pages = "6461--6464",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "24",

}

TY - JOUR

T1 - Bone marrow-derived CMPs and GMPs represent highly functional proangiogenic cells

T2 - Implications for ischemic cardiovascular disease

AU - Wara, Akm Khyrul

AU - Croce, Kevin

AU - Foo, Shi Yin

AU - Sun, Xinghui

AU - Icli, Basak

AU - Tesmenitsky, Yevgenia

AU - Esen, Fehim

AU - Rosenzweig, Anthony

AU - Feinberg, Mark W.

PY - 2011/12/8

Y1 - 2011/12/8

N2 - Clinical studies using bone marrow-derived proangiogenic cells (PACs) have demonstrated modest improvements of function and/or perfusion of ischemic myocardium or skeletal muscle. Because the identities of these PACs and their functional ability to promote neovascularization remain poorly understood, it is possible that a subset of robust PACs exists but is obscured by the heterogeneous nature of this cell population. Herein, we found that common myeloid progenitors (CMPs) and granulocyte-macrophage progenitors (GMPs) preferentially differentiate into PACs compared with megakaryocyte-erythrocyte progenitors, hematopoietic stem cells, and common lymphoid progenitors. In vivo hindlimb ischemia studies and Matrigel plug assays verified the enhanced neovascularization properties uniquely associated with PACs derived from CMPs and GMPs. Taken together, these observations identify CMPs and GMPs as key bone marrow progenitors for optimal PAC function in vitro and in vivo and provide a foundation for novel therapeutic approaches to modulate angiogenesis.

AB - Clinical studies using bone marrow-derived proangiogenic cells (PACs) have demonstrated modest improvements of function and/or perfusion of ischemic myocardium or skeletal muscle. Because the identities of these PACs and their functional ability to promote neovascularization remain poorly understood, it is possible that a subset of robust PACs exists but is obscured by the heterogeneous nature of this cell population. Herein, we found that common myeloid progenitors (CMPs) and granulocyte-macrophage progenitors (GMPs) preferentially differentiate into PACs compared with megakaryocyte-erythrocyte progenitors, hematopoietic stem cells, and common lymphoid progenitors. In vivo hindlimb ischemia studies and Matrigel plug assays verified the enhanced neovascularization properties uniquely associated with PACs derived from CMPs and GMPs. Taken together, these observations identify CMPs and GMPs as key bone marrow progenitors for optimal PAC function in vitro and in vivo and provide a foundation for novel therapeutic approaches to modulate angiogenesis.

UR - http://www.scopus.com/inward/record.url?scp=83455225455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83455225455&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-06-363457

DO - 10.1182/blood-2011-06-363457

M3 - Article

VL - 118

SP - 6461

EP - 6464

JO - Blood

JF - Blood

SN - 0006-4971

IS - 24

ER -